



an Open Access Journal by MDPI

Killing It Softly—New Approaches to Overcome Cancer Chemoresistance

Guest Editors:

Dr. Beata Pajak

Independent Laboratory of
Molecular Biology and Genetics,
Kaczkowski Military Institute of
Hygiene and Epidemiology,
Kozielska 4, 01-183 Warsaw,
Poland

Dr. Anna Jaśkiewicz

Independent Laboratory of
Genetics and Molecular Biology,
Kaczkowski Military Institute of
Hygiene and Epidemiology,
Kozielska 4, 01-183 Warsaw,
Poland

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editors

Oncological therapy is an unequal fight with a dangerous opponent. In response to chemotherapeutic drugs or radiotherapy, cancer cells activate several molecular mechanisms that ensure survival and further cancer progression. Examples of mechanisms determining chemo- and radio-resistance include the constitutive activity of survival factors, namely: NF- κ B, pSTAT3, expression of MDR multidrug resistance proteins, glycolytic phenotype, shedding of TNF family death-ligand receptors, and many others. Because of the wealth of protective mechanisms, the available chemotherapeutic agents do not meet the need for effective cancer elimination. Therefore, there is an urgent need for the continuous improvement of anti-cancer therapy to reduce the phenomenon of chemoresistance and to effectively attack cancer cells. In the development of medicine, biotechnology, nanomedicine, and molecular biology techniques, anti-cancer therapy progress is also significant.

We cordially invite authors in the field to submit original research or review articles pertaining to this field of biomedicine.



mdpi.com/si/73357



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)